FTC Orders Baxter to Divest Rights to Two Drugs as Part of Claris Takeover

September 5, 2017

Baxter International will divest the rights to two drugs held by Claris Lifesciences to offset the anticompetitive effects of its acquisition of Claris, under terms of a final FTC order.

The products are fluconazole in saline intravenous bags, which is used to treat fungal and yeast infections, and intravenous milrinone, which dilates blood vessels and reduces blood pressure and is used as a short-term treatment for life-threatening heart failure.

The rights will be divested to Renaissance Lakewood, of Newtown, Pennsylvania.

View today's stories